Loading...
Loading...
Also known as: Ozempic, Wegovy, Rybelsus, GLP-1 agonist
Long-acting GLP-1 receptor agonist that reduces appetite, improves glycemic control, and promotes significant weight loss.
Benefits
6
Conditions
5
Evidence
Multiple large RCTs (STEP, SUSTAIN trials), FDA approved+ studies
Source
Synthetic GLP-1 receptor agonist
Gabriel Brain Score
Strong
Long-acting GLP-1 receptor agonist that reduces appetite, improves glycemic control, and promotes significant weight loss.
Binds GLP-1 receptors in pancreas and brain, increases insulin secretion and decreases glucagon, slows gastric emptying for prolonged satiety, acts on hypothalamic appetite centers to reduce food intake, 94% homology to native GLP-1 with modifications for extended half-life (7 days).
* Dosing should be individualized. Always consult with a qualified healthcare practitioner.
Multiple large RCTs (STEP, SUSTAIN trials), FDA approved
Robust clinical evidence from STEP trials showing 15-20% weight loss. FDA approved for diabetes (Ozempic) and obesity (Wegovy). SUSTAIN-6 showed cardiovascular benefits. Extensive safety data in diverse populations.
Investigational triple agonist targeting GIP, GLP-1, and glucagon receptors for maximal metabolic benefit and weight loss.
Dual GIP and GLP-1 receptor agonist that produces superior weight loss and glycemic control compared to GLP-1 agonists alone.
Investigational dual glucagon and GLP-1 receptor agonist for obesity and metabolic dysfunction-associated steatohepatitis (MASH).